

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



遠東控股國際有限公司

Far East Holdings International Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 36)

APPOINTMENTS OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board announces the following appointments with effect from 1 December 2014:

- Dr. Wong Yun Kuen has been appointed as an independent non-executive Director and a member of Audit Committee of the Company; and
- Ms. Kwan Shan has been appointed as an independent non-executive Director and a member of Audit Committee of the Company.

Following the appointments of Dr. Wong and Ms. Kwan, the Board has fulfilled the requirements under Rule 3.10(1) and 3.10A of the Listing Rules, which require the minimum number of the independent non-executive Directors and the requirement under Rule 3.21 of the Listing Rules, which requires the minimum number of the Audit Committee.

References are made to announcements of Far East Holdings International Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 21 October 2014, 12 November 2014 and 14 November 2014.

APPOINTMENTS OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that Dr. Wong Yun Kuen (“**Dr. Wong**”) has been appointed as an independent non-executive Director and a member of the audit committee of the Company (the “**Audit Committee**”) and Ms. Kwan Shan (“**Ms. Kwan**”) has also been appointed as an independent non-executive Director and a member of the Audit Committee with both effect from 1 December 2014.

Dr. Wong Yun Kuen

Dr. Wong, aged 57, received his Ph.D. degree from Harvard University, and was “Distinguished Visiting Scholar” at Wharton School of the University of Pennsylvania. Dr. Wong has worked in financial industries in the United States and Hong Kong for many years, and has considerable experience in corporate finance, investment and derivative products. He is a member of the Hong Kong Securities and Investment Institute.

Dr. Wong is an executive director of UBA Investments Limited (stock code: 768), and an independent non-executive director of Harmony Asset Limited (stock code: 428), Bauhaus International (Holdings) Limited (stock code: 483), China Yunnan Tin Minerals Group Company Limited (stock code: 263), Kingston Financial Group Limited (stock code: 1031), Guocang Group Limited (stock code: 559), Sincere Watch (Hong Kong) Limited (stock code: 444) and China Sandi Holdings Limited (stock code: 910). The securities of the above companies are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Dr. Wong is also an independent non-executive director of Kaisun Energy Group Limited (stock code: 8203), whose securities are listed on the Growth Enterprise Market (the “**GEM**”) of the Stock Exchange.

Dr. Wong was an independent non-executive director of Hong Kong Life Sciences and Technologies Group Limited (stock code: 8085) from November 2009 to September 2012, whose securities are listed on the GEM of the Stock Exchange, and was also an independent non-executive director of KuangChi Science Limited (stock code: 439), from June 2007 to August 2014, Kong Sun Holdings Limited (stock code: 295), from April 2007 to November 2014 and New Island Development Holdings Limited (stock code: 377), from October 2010 to September 2014, the securities of these companies are listed on the Main Board of the Stock Exchange.

Dr. Wong has entered into a letter of appointment with the Company for a term of 1 year commencing on 1 December 2014. He is subject to retirement and re-election in the annual general meeting of the Company in accordance with the articles of association of the Company. Dr. Wong is entitled to receive a monthly director’s fee of HK\$10,000 subject to further adjustment if additional appointments are made. Such fee is determined and subject to review by the Board and the remuneration committee of the Company (the “**Remuneration Committee**”) from time to time with reference to his duties and responsibilities with the Company.

Saved as disclosed above, (i) Dr. Wong has not held any directorships in any other listed public companies in Hong Kong or overseas in the last three years; (ii) he does not have any interests in the Company’s shares within the meaning of Part XV of the Securities and Futures Ordinance; (iii) he does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange) of the Company; and (iv) he does not hold other positions with other members of the Group.

Saved as disclosed above, the Board is not aware of any other matters in relation to the appointment of Dr. Wong that need to be brought to the attention of the Shareholders and there is no information in respect of Dr. Wong which is required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

Ms. Kwan Shan

Ms. Kwan, aged 43, has more than 16 years of experience in the accounting and finance field in listed companies. Ms. Kwan holds a Bachelor's Degree in Accountancy from Hong Kong Polytechnic University and is a fellow member of the Association of Chartered Certified Accountants. Ms. Kwan is currently a company secretary of Yueshou Environmental Holdings Limited (stock code: 1191), whose securities are listed on the Main Board of the Stock Exchange.

Ms. Kwan has entered into a letter of appointment with the Company for a term of 1 year commencing on 1 December 2014. She is subject to retirement and re-election in the annual general meeting of the Company in accordance with the articles of association of the Company. Ms. Kwan is entitled to receive a monthly director's fee of HK\$10,000 subject to further adjustment if additional appointments are made. Such fee is determined and subject to review by the Board and the Remuneration Committee of the Company from time to time with reference to her duties and responsibilities with the Company.

Saved as disclosed above, (i) Ms. Kwan has not held any directorships in any other listed public companies in Hong Kong or overseas in the last three years; (ii) she does not have any interests in the Company's shares within the meaning of Part XV of the Securities and Futures Ordinance; (iii) she does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Listing Rules on the Stock Exchange) of the Company; and (iv) she does not hold other positions with other members of the Group.

Saved as disclosed above, the Board is not aware of any other matters in relation to the appointment of Ms. Kwan that need to be brought to the attention of the Shareholders and there is no information in respect of Ms. Kwan which is required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

The Board would like to express its warmest welcome to Dr. Wong and Ms. Kwan in joining the Board.

Following the appointments of Dr. Wong and Ms. Kwan, the Board has fulfilled the requirements under Rule 3.10(1) and 3.10A of the Listing Rules, which require the minimum number of the independent non-executive Directors and the requirement under Rule 3.21 of the Listing Rules, which requires the minimum number of the Audit Committee.

By Order of the Board
Far East Holdings International Limited
Richard Yen
Managing Director

Hong Kong, 1 December 2014

As at the date of this announcement, the Board comprises eleven Directors, of which six are executive Directors, namely, Deacon Te Ken Chiu, J.P., Mr. Derek Chiu, Mr. Richard Yen, Mr. Yu Pak Yan, Peter, Mr. Fok Chi Tak and Mr. Ip Ngai Sang; one is non-executive Director, namely, Mr. Desmond Chiu; and four are independent non-executive Directors, namely, Mr. Eugene Yun Hang Wang, Mr. Chan Ming Sun, Jonathan, Dr. Wong Yun Kuen and Ms. Kwan Shan.